Genmab — Maj 2018
-
This Nivolumab / BMS study now takes out Pomalidomide, Dexamethasone , Currently, this study is only open to nivolumab+daratumumab vs daratumumab monotherapy https://clinicaltrials.gov/ct2/history/NCT01592370?A=60&B=61&C=Side-by-Side
-
Potential of VRD + Daratumumab in Myeloma - http://www.targetedonc.com/case-based-peer-perspectives/multiple-myeloma/chari-myeloma-treatment/potential-of-vrd-daratumumab-in-myeloma
-
I find this very interesting "for example, when VMP was approved many years ago, oncologists took that to be able to use bortezomib frontline, but many people weren’t necessarily giving the melphalan with it" http://www.targetedonc.com/case-based-peer-perspectives/multiple-myeloma/chari-myeloma-treatment/use-of-vmp-daratumumab-in-myeloma
-
@ Stockbull tak for dit svar. Jeg er skam investor. Men forsøger bare at forstå, udsvingne. Informationen om FDA godkendelsen er fra Syd Bank og deres oversigt https://data.sydbank.dk/api/investment/sydbank/publications/file/50139. Jeg melder mig naturligvis til Genmabs news. Tak og god dag

-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind